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Background: Orbital metastases are an uncommon finding, being present in just 9%
deceased patients with metastatic cancer. Only a quarter of patients with choroidal metas-
tases have bilateral disease. Parotid cancer is not a common form of head and neck malig-
nancy. Bilateral multifocal metastases from adenocarcinoma ex pleomorphic of parotid
gland have been documented just once before in the literature. We present a similar case
where palliative EBRT was used to gain local control with minimal toxicity.
Case Presentation:The case of a 45-year-old Caucasian gentleman who presented to his
general practitioner with otalgia and weight loss. Imaging revealed a mass in the deep lobe
of the left parotid gland, invading into the medial pterygoid muscle. PET–CT revealed locore-
gional and distant lymphatic involvement plus disseminated skeletal metastases. Lymph
node examination revealed adenocarcinoma ex pleomorphic histology.Within weeks of this
diagnosis, the patient developed rapidly progressive visual impairment. Ophthalmologists
found multifocal uveal masses bilaterally. Palliative fractions of external beam radiotherapy
were delivered to the orbits before combination chemotherapy. We discuss the patient’s
presentation, histopathology, and management, with support from the literature regarding
applied and related therapies.
Summary: In this rare presentation of disseminated malignancy affecting the choroid bilat-
erally, the authors demonstrate the application of palliative EBRT to good local effect. Given
the nature of this treatment and that of the metastases, in the setting of incurable disease
orbital morbidity is likely to occur again before the patient’s death. Awareness of the initial
symptoms is important to provide prompt care and maintain quality of life.
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INTRODUCTION
Macroscopic orbital metastases are an uncommon clinical find-
ing, but an autopsy series of patients with metastatic disease have
found microscopic metastases in approximately 9% of cases (1).
The uvea, the vascular middle layer of the eye is the most com-
mon site for orbital metastases. In a survey of 520 eyes (2) with
uveal metastases, the choroid was involved in 88%, the iris in 9%
and the ciliary body in 2%. Tumors most often occurred in the
posterior pole of the eye with an average of two tumors per eye.
A third of patients found to have orbital metastases have not yet
had a previous diagnosis of cancer (1). Only a quarter of patients
with choroidal metastases have bilateral disease (3), and these
are most likely to come from breast and lung primary malignan-
cies. In 42% of patients diagnosed with orbital metastases, there
was no previous evidence of systemic disease (4). After an estab-
lished diagnosis of orbital disease, there was a mean survival of
15 months. Parotid malignancy of acinic cell, mixed type, adenoid
cystic, epidermoid, and adenocarcinoma histologies affecting the
uvea have been presented as cases in the literature, all as monocu-
lar metastases. Bilateral choroidal metastases in adenocarcinoma
of the parotid gland have been reported just once before to the
best knowledge of the authors, 1 year following resection and irra-
diation of the patient’s tumor (5). Treatment in the case reports
includes surgical removal, enucleation, exenteration, plaque radio-
therapy, and conservative management. Herein, we describe the
use of palliative external beam radiotherapy to the orbits for bilat-
eral painless loss of vision caused by uveal metastases of parotid
malignancy in a young patient.
CASE PRESENTATION
A 45-year-old male architect and non-smoker presented to his
General Practitioner with a history of intermittent otalgia, and
weight loss of 20 kg in 1 year, attributed to wisdom tooth erup-
tion and lifestyle changes, respectively. He denied all other ear,
nose, and throat symptoms. Physical examination, including cra-
nial nerves, was unremarkable and routine blood parameters
were within normal limits. Assessment by an ENT surgeon was
also unremarkable but contrast magnetic resonance imaging of
the head revealed a 22 mm× 13 mm lesion in the deep lobe of
the left parotid gland invading into the medial pterygoid mus-
cle and causing effacement of the left parapharangeal space (see
Figure 1). Fine needle aspiration of the salivary gland lesion
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FIGURE 1 | Magnetic resonance imaging showing the left parotid
gland mass in the coronal plane.
was suggestive of adenoid cystic carcinoma and referral to clin-
ical oncology was made. An FDG PET–CT study was performed
and showed an FDG-avid soft tissue lesion in deep lobe of left
parotid of dimensions 2.0 cm× 2.5 cm with a SUVmax of 8.3.
There was an impression of internal calcification suggesting a long-
standing lesion. There was left sided cervical lymphadenopathy,
thoracic lymphadenopathy, and disseminated skeletal metastases.
Biopsy of two cervical nodes showed high grade metastatic ade-
nocarcinoma likely from a carcinoma ex pleomorphic adenoma
(see Figure 2). During staging investigations, the patient pre-
sented to an acute eye service complaining of bilateral, markedly
reduced visual acuity without pain. His previously 6/6 vision
had deteriorated to 6/15 (right) and 6/60 (left) [note that 6 m
are used in UK in contrast to 20 feet in the USA]. On fun-
doscopy, exudative retinal detachment was observed bilaterally
(see Figure 3). Fluorescein angiography identified the cause as
multiple choroidal metastases bilaterally. In the left eye, the fovea
was involved.
TREATMENT AND OUTCOMES
Due to the diffuse nature of the orbital metastases, palliative
EBRT was offered. The patient received 20 Gray of external
beam radiotherapy to his orbits in five fractions, using 6 MV
photons in parallel opposed lateral fields. Following adminis-
tration of orbital irradiation, the patient’s visual acuity exhib-
ited recovery to 6/9 on the left and 6/5 on the right, both
retinas became completely attached and the choroidal masses
were flattened. The only side effect experienced was dry eyes,
likely due to lacrimal gland irradiation. The patient was of
FIGURE 2 | Node histology (×250) demonstrating necrotic tissue, an
abundance of mitotic figures, and the impression of glandular
architecture (H&E).
performance status 1 and went on to receive six cycles of epiru-
bicin, cisplatin, and 5-fluorouracil chemotherapy plus palliative
radiotherapy to bone metastases when needed. He has recently
completed his chemotherapy. The patient remained at perfor-
mance status 1 throughout his treatment and experienced no
significant side effects from treatment, allowing him to con-
tinue to work part-time. CT imaging after cycle 6 showed sta-
ble disease and at 6 months post-diagnosis his vision remained
stable.
DISCUSSION
Tumors of the salivary glands account for approximately 5% of all
head and neck neoplasms. The average age of patients with malig-
nant neoplasm is approximately 55 years of age; for benign tumors,
approximately 40 years. One-quarter of parotid neoplasms are
malignant. Metastases are present in 20–25% of patients at the
time of diagnosis. Painless loss of visual acuity is the presenting
feature of uveal metastases in 75% patients with primary disease
of the breast (6). No symptoms are experienced in 7% cases. The
most common primary sites likely to contribute metastases to the
orbit can be viewed in Table 1 (2).
Common sites of metastasis for carcinoma ex pleomor-
phic include lung, bone, and liver (7). Choroidal metastases
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FIGURE 3 | Photograph of the right fundus, with evidence of two uveal
metastases.
Table 1 |The most common sources of metastases to the choroid.
Primary site Number of men Number of women Total (%)
Breast 2 194 196 (47)
Lung 55 35 90 (22)
Gastrointestinal 13 5 18 (4)
Kidney 8 1 9 (2)
Skin (melanoma) 5 4 9 (2)
Prostate 9 0 9 (2)
Others 5 11 16 (4)
Unknown 40 33 73 (17)
Total 137 283 420
in this patient may be considered evidence of hematogenous
dissemination further to the widespread bone disease, as the orbit
has a limited lymphatic system (8). The areas of calcification
observed in some tissue samples and on PET–CT indicate that the
patient most likely had an undetected pleomorphic adenoma for
some time. These tumors’ benign nature and indolent course with
potential for malignant transformation are well-known. These
tumors typically present later than seen in this case, in the sixth to
eighth decades.
Orbital irradiation is the main treatment option for choroidal
metastases and is mostly delivered by external beam irradiation.
Stereotactic radiation therapy is also an option but would be dif-
ficult to deliver in the emergency situation when patients present
with acute visual loss and also on account that metastases are
usually multiple and also bilateral in half of cases. Stereotactic
radiotherapy is also associated with significantly higher rates of
orbital morbidity at 4 years, in a study of orbital melanoma (9).
Response rates to orbital radiation treatment are high but overall
survival is generally poor on account of systemic disease. A retro-
spective case series of 264 breast cancer patients with uveal metas-
tases showed regression in 64% cases following external beam
radiotherapy, and 65% following systemic treatments (6). Exter-
nal beam radiotherapy technical factors such as higher biologically
effective dose, lower treatment energy, and whole globe (versus
lens-sparing) technique do not predispose eyes to complications
of irradiation including cataracts (10). This is likely to be related
to the poor survival rates for malignant disease with choroidal
secondaries.
Irradiation is also administered by brachytherapy, using surgi-
cally introduced (and removed) plaques (2).This data delineates
effectiveness both as primary treatment, and as salvage treatment
when EBRT has failed. Radiation retinopathy, radiation papillopa-
thy, or both were found in three patients (8%) and occurred at a
mean of 8 months after treatment. Similar results were found in a
more recent study quantifying EBRT toxicity (11). Other authors
indicate that the development of pathology in keeping with radia-
tion retinopathy is related to tumor volume (12), based on findings
of up to 60% patients receiving plaque therapy developing the
complication.
A group at the Liverpool Ocular Oncology Centre enjoyed suc-
cess in two patients using Ruthenium-106 included in a recently
published study (13). It was in this center over two decades ago that
proton therapy was first used as a treatment of malignancy. Data
from the Loma Linda centre in California indicates that proton
therapy can be used safely and effectively to treat uveal primary
tumors (14). In a study of 78 singular orbital melanomas, local
control at 5 years was found by authors there to be 90.5%, and eye
preservation was achieved in 75.3%. Useful visual acuity remained
with 49.1% at the 5-year point.
Other centers use laser therapies in the form of transpupil-
lary thermotherapy, photocoagulation, and photodynamic ther-
apy (15), however, data on these limited at present. As cancer
survivorship continues to improve and the incidence of orbital
metastases increases, these treatments may play an important part
in the future management of orbital metastases.
Unfortunately, in some clinical settings enucleation or exen-
teration is the most appropriate management. Due to the diffuse
nature of the metastases in the case presented, it was felt EBRT
offered the best chance of local control. Combination chemother-
apy was offered to gain control of systemic disease – with the aim
of extending survival. Throughout this time period, the clinicians
involved must be vigilant for orbital morbidity, as a result of local
relapse, and of the EBRT outlined (16, 17).
There are very few clinical trials investigating the use of systemic
therapy in salivary gland cancers. Combination chemotherapy
with epirubicin, cisplatin, and 5-fluorouracil is a regime used in
the Northern Ireland Cancer Centre for metastatic salivary gland
carcinoma and objective responses seen are similar to the litera-
ture at approximately 30% but are of short duration. Objective
response rates are similar to other regimens reported in the liter-
ature. Demirci et al. (6) found systemic survival rates for breast
cancer patients with uveal metastasis were 65% at 1-year, 34% at
3-year, and 24% at 5-year follow-up.
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CONCLUDING REMARK
In summary, the above case demonstrates that new visual signs
or symptoms should be investigated thoroughly in patients with
parotid malignancy and good responses to orbital irradiation can
be obtained with palliative fractionation regime.
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